In addition to L1152R, additional nonoverlapping ALK kinase domain mutations L1196M and C1156Y which confer resistance to crizotinib have been detected in patients with ALK fusion-positive NSCLC [87]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.